Skip to main content
SpringerLink
Log in

The Authors’ Reply

  • Correspondence
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Meulendijks D, Mannesse CK, Jansen PAF, et al. Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf 2010; 33: 101–14

    Article  PubMed  CAS  Google Scholar 

  2. Jessani M, Montgomery J, Fedde JD, et al. Lack of association between antipsychotics and hyponatremia in chronic schizophrenia. Schizophr Res 2006; 83: 307–9

    Article  PubMed  Google Scholar 

  3. von Elm E, Altman DG, Egger M, et al., for the STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008 Apr; 61(4): 344–9

    Article  Google Scholar 

  4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug; 30(2): 239–45

    Article  PubMed  CAS  Google Scholar 

  5. Goldman MB. The mechanism of life-threatening water imbalance in schizophrenia and its relationship to the underlying psychiatric illness. Brain Res Rev 2010; 61: 210–20

    Article  Google Scholar 

  6. Mannesse CK, van Puijenbroek EP, Jansen PAF, et al. Hyponatraemia as an adverse drug reaction of antipsychotics: a case-control study in VigiBase. Drug Saf 2010; 33: 569–78

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest to declare that are directly relevant to the content of this letter.

Author information

Authors and Affiliations

  1. Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, the Netherlands

    Didier Meulendijks & Toine C.G. Egberts

  2. Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, the Netherlands

    Didier Meulendijks & Toine C.G. Egberts

  3. Department of Geriatric Medicine, Vlietland, Schiedam, the Netherlands

    Cyndie K. Mannesse

  4. Department of Geriatric Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands

    Paul A. F. Jansen & Rob J. van Marum

Authors
  1. Didier Meulendijks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cyndie K. Mannesse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul A. F. Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rob J. van Marum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toine C.G. Egberts
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meulendijks, D., Mannesse, C.K., Jansen, P.A.F. et al. The Authors’ Reply. Drug-Safety 34, 354–355 (2011). https://doi.org/10.2165/11589120-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11589120-000000000-00000

Keywords

Search

Navigation